매출 성장 + 마진 확대 + FCF 양수
Positive매출이 +5.4% 성장하면서 영업이익률이 1.0%에서 1.8%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.
Evidence
매출 YoY +5.4%영업이익률 1.0%→1.8%FCF 294
ICU Medical
ICUI-US · Nasdaq$168.51+0.08%
2026-07-31 closeICU Medical — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
CloseMA20MA60MA120
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Why this signalSignal guide
Moving-average alignment
Yes · score 0.72
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p
Beat the market on 57.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 759 건강관리 peers · not investment advice
Valuation in its own history
PER — · PBR 2.12 — own history (2000-01~) percentiles 4/100 · 76/100
PER4/100
PBR76/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.91
Distress
Grey
Safe
- Altman Z''
- 2.91
- Beneish M-Score
- -2.79
- Sloan accrual
- -7.65%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROANot passed
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 252% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-08-03건강관리
This stock is in 건강관리: revenue rank 87 of 553, share 0.1%.
87 / 5530.1%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6ICU Medical0.1%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 22
Value lens
- P90/P10
- 23.8
- Median P/B
- 3.07
- Level
- 넓음
- n
- 467
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 1.8%
- Interest coverage
- 0.4x
- Return on equity (ROE)
- -6%
Operating margin −5pp
Operating lossInterest coverageBase 0.4x adverse case -0.7x
Return on equity (ROE)Base -6% adverse case -9.3%
Revenue −15%
Interest coverage riskInterest coverageBase 0.4x adverse case 0.3x
Return on equity (ROE)Base -6% adverse case -3.6%
Interest rate +2pp
Interest coverage riskInterest coverageBase 0.4x adverse case 0.3x
Return on equity (ROE)Base -6% adverse case -5.5%
Interest coverage limit
Already below the limit by 2.7ppInterest coverage limit at an operating margin of 4.5%
Interest expense coverage threshold
Financials at a glance
ICU Medical's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
🔗 See in the full market map →Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
52-week high breakout×5
26-07-30·26-07-29·26-07-28·26-07-16·26-07-06·
Golden cross×1
26-07-13·
New MA alignment×2
26-07-24·26-07-21·
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy